The VP, CFO of ADMA Biologics (NASDAQ: ADMA) is Buying Shares

By Carrie Williams

Yesterday, the VP, CFO of ADMA Biologics (NASDAQ: ADMA), Brian Lenz, bought shares of ADMA for $13.98K.

Following this transaction Brian Lenz’s holding in the company was increased by 76.47% to a total of $37.2K. In addition to Brian Lenz, one other ADMA executive reported Buy trades in the last month.

Based on ADMA Biologics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $4.73 million and GAAP net loss of $15.2 million. In comparison, last year the company earned revenue of $2.94 million and had a GAAP net loss of $4.33 million. The company has a one-year high of $6.88 and a one-year low of $2.01. Currently, ADMA Biologics has an average volume of 239.2K.

Four different firms, including Ladenburg and Maxim Group, currently also have a Buy rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. is a biopharmaceutical company, which develops, manufactures and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the Plasma Collection Center and Research and Development segments. The Plasma Collection Center segment comprises of operations in Georgia.